A pasteurized therapeutic plasma

M. Burnouf-Radosevich, T. Burnouf, J. J. Huart

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A process to subject pooled human plasma to a viral inactivation treatment by heating in the liquid state for 10 hrs at 60°C (pasteurization) has been designed and evaluated. Activity recovered from clotting factors and protease inhibitors exceeded 80%. Overall clotting activity remained good. No activation of coagulation factors was detected. The process did not generate aggregates. No side effects (toxicity. hypotension, variation in heart rate, thrombogenicity) could be detected in animal models. Virus kill studies, using 7 lipid-enveloped and non-enveloped viruses including HIV-1 and Sindbis virus, revealed inactivation levels similar to those obtained for plasma derivatives. Thus, pasteurisation of human plasma can be achieved in conditions that allow good recovery of biological properties while ensuring a high degree of inactivation of lipid-enveloped and non-enveloped viruses.

Original languageEnglish
Pages (from-to)91-94
Number of pages4
JournalTransfusion Medicine and Hemotherapy
Volume19
Issue number2
DOIs
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

Virus Inactivation
Pasteurization
Blood Coagulation Factors
Viruses
Sindbis Virus
Lipids
Protease Inhibitors
Hypotension
Heating
HIV-1
Therapeutics
Animal Models
Heart Rate

Keywords

  • Fresh frozen plasma
  • Pasteurization
  • Virus inactivation

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

A pasteurized therapeutic plasma. / Burnouf-Radosevich, M.; Burnouf, T.; Huart, J. J.

In: Transfusion Medicine and Hemotherapy, Vol. 19, No. 2, 1992, p. 91-94.

Research output: Contribution to journalArticle

Burnouf-Radosevich, M. ; Burnouf, T. ; Huart, J. J. / A pasteurized therapeutic plasma. In: Transfusion Medicine and Hemotherapy. 1992 ; Vol. 19, No. 2. pp. 91-94.
@article{a51493da606e486a80e4e4fc4bdb905c,
title = "A pasteurized therapeutic plasma",
abstract = "A process to subject pooled human plasma to a viral inactivation treatment by heating in the liquid state for 10 hrs at 60°C (pasteurization) has been designed and evaluated. Activity recovered from clotting factors and protease inhibitors exceeded 80{\%}. Overall clotting activity remained good. No activation of coagulation factors was detected. The process did not generate aggregates. No side effects (toxicity. hypotension, variation in heart rate, thrombogenicity) could be detected in animal models. Virus kill studies, using 7 lipid-enveloped and non-enveloped viruses including HIV-1 and Sindbis virus, revealed inactivation levels similar to those obtained for plasma derivatives. Thus, pasteurisation of human plasma can be achieved in conditions that allow good recovery of biological properties while ensuring a high degree of inactivation of lipid-enveloped and non-enveloped viruses.",
keywords = "Fresh frozen plasma, Pasteurization, Virus inactivation",
author = "M. Burnouf-Radosevich and T. Burnouf and Huart, {J. J.}",
year = "1992",
doi = "10.1159/000222590",
language = "English",
volume = "19",
pages = "91--94",
journal = "Transfusion Medicine and Hemotherapy",
issn = "1660-3796",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - A pasteurized therapeutic plasma

AU - Burnouf-Radosevich, M.

AU - Burnouf, T.

AU - Huart, J. J.

PY - 1992

Y1 - 1992

N2 - A process to subject pooled human plasma to a viral inactivation treatment by heating in the liquid state for 10 hrs at 60°C (pasteurization) has been designed and evaluated. Activity recovered from clotting factors and protease inhibitors exceeded 80%. Overall clotting activity remained good. No activation of coagulation factors was detected. The process did not generate aggregates. No side effects (toxicity. hypotension, variation in heart rate, thrombogenicity) could be detected in animal models. Virus kill studies, using 7 lipid-enveloped and non-enveloped viruses including HIV-1 and Sindbis virus, revealed inactivation levels similar to those obtained for plasma derivatives. Thus, pasteurisation of human plasma can be achieved in conditions that allow good recovery of biological properties while ensuring a high degree of inactivation of lipid-enveloped and non-enveloped viruses.

AB - A process to subject pooled human plasma to a viral inactivation treatment by heating in the liquid state for 10 hrs at 60°C (pasteurization) has been designed and evaluated. Activity recovered from clotting factors and protease inhibitors exceeded 80%. Overall clotting activity remained good. No activation of coagulation factors was detected. The process did not generate aggregates. No side effects (toxicity. hypotension, variation in heart rate, thrombogenicity) could be detected in animal models. Virus kill studies, using 7 lipid-enveloped and non-enveloped viruses including HIV-1 and Sindbis virus, revealed inactivation levels similar to those obtained for plasma derivatives. Thus, pasteurisation of human plasma can be achieved in conditions that allow good recovery of biological properties while ensuring a high degree of inactivation of lipid-enveloped and non-enveloped viruses.

KW - Fresh frozen plasma

KW - Pasteurization

KW - Virus inactivation

UR - http://www.scopus.com/inward/record.url?scp=84940618286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940618286&partnerID=8YFLogxK

U2 - 10.1159/000222590

DO - 10.1159/000222590

M3 - Article

VL - 19

SP - 91

EP - 94

JO - Transfusion Medicine and Hemotherapy

JF - Transfusion Medicine and Hemotherapy

SN - 1660-3796

IS - 2

ER -